ArticlePharmacoEconomics2021
The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer.
Katrine Wallace et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this paperpooled itcites it